Has Regeneron Stock Become A Different Bet?
For questions about this article or underlying research, email help@trefis.com. Regeneron Pharmaceuticals (REGN) stock trades at 19.2 times earnings, against 22.9 for the S&P 500. Shareholders paying that price need to know what they are buying, and the company’s priorities have changed. As recently as its February 2025 call, management discussed preserving market share for […]